TTD | Drug: D04TEF

Drug General Information
Drug ID	D04TEF
Former ID	DIB011814
Drug Name	Alpha-1 antitrypsin
Synonyms	AAT, Transgene; Alpha-1 antitrypsin, Transgene
Indication	Blood coagulation disorders [ICD10:D65-D68]		Phase 2	[526002]
Company	Transgene SA
Target and Pathway
Target(s)	Trypsin	Target Info	Modulator	[526791], [549592], [550162]
KEGG Pathway	Neuroactive ligand-receptor interaction
	Pancreatic secretion
	Protein digestion and absorption
	Influenza A
Reactome	Activation of Matrix Metalloproteinases
Reactome	Cobalamin (Cbl, vitamin B12) transport and metabolism
WikiPathways	Activation of Matrix Metalloproteinases
References
Ref 526002	Technology evaluation: transgenic alpha-1-antitrypsin (AAT), PPL therapeutics. Curr Opin Mol Ther. 2000 Apr;2(2):199-204.
Ref 526791	Expression of human alpha 1 antitrypsin in transgenic sheep. Cytotechnology. 1992;9(1-3):77-84.
Ref 549592	US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
Ref 550162	EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information